about
Recent advances in metabolic and bariatric surgeryMetabolic responses to exogenous ghrelin in obesity and early after Roux-en-Y gastric bypass in humans.Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis.Ileal interposition improves glucose tolerance and insulin sensitivity in the obese Zucker rat.A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery.Early Increases in Bile Acids Post Roux-en-Y Gastric Bypass Are Driven by Insulin-Sensitizing, Secondary Bile Acids.Jejunal administration of glucose enhances acyl ghrelin suppression in obese humansPleural effusion following blunt splenic injury in the pediatric trauma population.Arginine-Dual roles as an onconutrient and immunonutrient.Bile acids and bariatric surgery.Proline Precursors and Collagen Synthesis: Biochemical Challenges of Nutrient Supplementation and Wound Healing.What is the impact on the healthcare system if access to bariatric surgery is delayed?Bile diversion, a bariatric surgery, and bile acid signaling reduce central cocaine rewardSurgical treatment of obesityDoes Bariatric Surgery Affect Breast-Milk Composition?The incidence of orthostatic intolerance after bariatric surgeryComment on: greater curvature as a gastric pouch for sleeve gastrectomy: a novel bariatric procedure. Feasibility study in a canine modelRoux-en-Y gastric bypass surgery improves hepatic glucose metabolism and reduces plasma kisspeptin levels in morbidly obese patients with type 2 diabetesMetabolic Effects of Bile Acids: Potential Role in Bariatric SurgeryRole of Bile Acids and GLP-1 in Mediating the Metabolic Improvements of Bariatric Surgery
P50
Q26745203-EC8CF2E5-066A-4489-8BB3-5B25E52076B2Q30252857-C35914A0-6D7A-4314-8F60-84796706F74CQ33942644-02B7E0B6-90C7-4B56-9EDA-924C27872649Q34178868-C0C3DCC9-9408-4979-99E1-9E8F184D4E03Q35156543-DBA3EE91-8E68-4C33-9432-743FF2F22407Q35703158-78FE1C8E-3AA0-4508-900E-2FF226066BE1Q36060415-1C73A21E-3846-4AD8-90A1-27B25BA7C04FQ37139405-F016A825-AACC-4B35-828E-FF8A254A1E14Q38242358-B61C6DFA-DD9D-4520-840C-F355BA987EBBQ39012828-0530E46B-D087-4C84-A678-587766D7E786Q39228891-7B7A70BE-BA55-48FA-BE73-F520190210B2Q47696667-4C7FC386-9CFC-463B-8E56-B0E6FDEA2600Q53727476-0B8AD825-35BF-430B-B08E-A9E80B339658Q57114151-C61D3B4A-923A-424D-AE24-00A8D9ECE34BQ89109805-3AF23AB2-B09C-4968-8D0D-103D92F21230Q89458133-8E232F69-2015-43E0-BDD9-348CABA8C35CQ90015487-77011FDA-E029-4328-8166-6E1F7A8DAD4DQ90460447-201C906A-5B7E-4F58-B2C3-8608A4EFB60EQ91222541-CFCA52A5-603B-46F3-9C78-814613ADD3C8Q91919560-FDDCDC60-0FEC-4818-ADEC-A6CB9175376DQ93174230-B3B01588-8500-4C7B-9E3C-9316807A5589
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Vance L Albaugh
@ast
Vance L Albaugh
@en
Vance L Albaugh
@es
Vance L Albaugh
@nl
type
label
Vance L Albaugh
@ast
Vance L Albaugh
@en
Vance L Albaugh
@es
Vance L Albaugh
@nl
prefLabel
Vance L Albaugh
@ast
Vance L Albaugh
@en
Vance L Albaugh
@es
Vance L Albaugh
@nl
P106
P1153
14057550500
P31
P496
0000-0002-5267-8951